Pharvaris N.V. (NASDAQ:PHVS) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Pharvaris N.V. (NASDAQ:PHVS) have received an average rating of “Moderate Buy” from the ten analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $37.5714.

A number of brokerages have recently commented on PHVS. Wall Street Zen raised shares of Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a research note on Thursday, November 13th. Citigroup reaffirmed a “market outperform” rating on shares of Pharvaris in a research note on Wednesday, November 19th. Finally, JMP Securities reduced their price objective on Pharvaris from $55.00 to $52.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 13th.

Pharvaris Price Performance

NASDAQ PHVS opened at $24.12 on Wednesday. Pharvaris has a 1 year low of $11.51 and a 1 year high of $28.63. The stock has a market capitalization of $1.26 billion, a PE ratio of -7.51 and a beta of -2.80. The company’s 50 day simple moving average is $23.60 and its two-hundred day simple moving average is $21.42.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.08. On average, research analysts anticipate that Pharvaris will post -2.71 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. TD Asset Management Inc boosted its position in Pharvaris by 27.4% during the second quarter. TD Asset Management Inc now owns 99,510 shares of the company’s stock valued at $1,751,000 after buying an additional 21,388 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in shares of Pharvaris in the 2nd quarter valued at about $57,000. Palumbo Wealth Management LLC boosted its holdings in Pharvaris by 3.2% during the 2nd quarter. Palumbo Wealth Management LLC now owns 14,549 shares of the company’s stock valued at $256,000 after acquiring an additional 447 shares during the period. Deutsche Bank AG boosted its holdings in Pharvaris by 55.1% during the 1st quarter. Deutsche Bank AG now owns 28,174 shares of the company’s stock valued at $442,000 after acquiring an additional 10,006 shares during the period. Finally, Baker BROS. Advisors LP bought a new position in Pharvaris during the 3rd quarter worth approximately $9,356,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.